^
Association details:
| Biomarker: | WT1 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Zeltherva (galinpepimut-S) (Wilms tumor 1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PHASE 1/2 STUDY OF GALINPEPIMUT-S PLUS PEMBROLIZUMAB COMBINATION IN PATIENTS WITH WT1+ PLATINUM-RESISTANT OVARIAN CANCER IN 2ND/3RD LINE OF THERAPY
Published date:
10/18/2023
Excerpt:
Efficacy: N=16: ORR=6.3% (versus 11.5% in comparable patients given pembrolizumab alone in KEYNOTE-028); disease control rate (ORR + stable disease) was 50% with a 14.4-month median follow-up. Median PFS and OS were 2.8 and 18.4 months, respectively versus 1.9 and 13.8 months in KEYNOTE-028, correspondingly. Immune response: N=14: post-GPS increments in WT1-reactive CD8/CD4 cell frequencies in 42.8%/85.7% of patients...GPS/pembrolizumab combination was safe & highly immunogenic and showed modest clinical benefit in patients with measurable advanced platinum-resistant OC.
Title:
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications
Published date:
12/21/2020
Excerpt:
SELLAS Life Sciences Group, Inc...today announced initial data from two clinical studies of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies in patients...with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression Free Survival at 6 Weeks...
